Comparing Effects of Different Doses of Vancomycin on the Biomarkers of Acute Kidney Injury
,
Abstract
Background: Effects of different doses of vancomycin on the renal biomarkers (Cys-C and KIM-1) of acute kidney injury were compared in patients with severe bacterial infections.|
Methods: Serum levels of Cys-C, KIM-1 and creatinine and urine level of Cys-C were measured at baseline and every other day in patients receiving different doses (15 mg/kg every 8 or 12h) of vancomycin.
Results: Level of serum Cys-C demonstrated significant increased during vancomycin treatment in both groups. However, there was no significant difference between the groups regarding serum Cys-C level. Urine Cys-C level neither changed significantly within nor between groups during vancomycin treatment. The same results were detected for serum KIM-concentrations.
Conclusion: Different doses of vancomycin showed comparable effects on the serum and urine biomarkers of acute kidney injury.
1. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39(9): 1267-84.
2. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49(3): 325-7.
3 Okamoto G, Sakamoto T, Kimura M, et al . Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients. Clin Biochem 2007;40(7):485-90.
4. Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity. A review. Med Toxicol Adverse Drug Exp 1998;3(5):376–86.
5. Ragab AR, Al-Mazroua MK. Incidence and predisposing factors of vancomycin-induced nephrotoxicity in children. Infect Dis Ther 2013; 2(1): 37–46.
6. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 2012;68(9):1243–55.
7. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52(4):1330–6.
8. Fagon J, Patrick H, Haas DW. Treatment of Gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000;161:753–62.
9. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU- 100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multi-center study. Clin Infect Dis 2001;32(3):402–12.
10. Tanaka A, Aiba T, Otsuka T, et al. Population pharmacokinetic analysis of vancomycin using serum cystatin-C as a market of renal function. Antimicrob Agents Chemother 2010;54(2):778-82.
11. Chung JY, Jin SJ, Yoon JH, Song YG. Serum cystatin C is a major predictive of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations. J Korean Med Sci 2013;28(1):45-54.
12. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med 2010;123(2): 182 e1-7.
13. Khan E, Batuman V, Lertora JJ. Emergence of biomarkers in nephropharmacology. Biomark Med 2010;4(6) 805-14.
14. Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycinassociated nephrotoxicity: a critical appraisal of risk with highdose therapy. Int J Antimicrob Agents 2011;37(2):95–101.
15. Uchida K, Gotoh A. Measurement of cystatin-C and creatinine in urine. Clin Chim Acta 2002; 323(1-2): 121-8.
16. Larsson A, Malm J, Grubb A, Hansson L. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Invest 2004;64(1):25-30.
17. Filler G, Bokenkamp A, Hofmann W, Bricon TL, Martinez-Bru C, Grubb A .Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem 2005;38(1):1-8.
18. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65(4):1416-21.
19. Jin SJ, Bae SC, Kim HW, et al. Evaluation of the effect of initial dose of vancomycin using serum Cystatin C as a marker in elderly patients. Infection and Chemotherapy 2009;41(4):224-9.
20. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV .Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002; 62(1): 237-44.
21. Vaidya VS, Ozer JS, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarkers qualification studies. Nat Biothecnol 2010;28(5):478-85.
22. Zimmermann AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacother 1995;15(1):85–91.
23. Huanga LY, Wanga CY, Jangb TN, Yeh HL. Nephrotoxicity of vancomycin and teicoplanin alone and in combination with an aminoglycoside. Taiwan Pharmaceutical Journal 2007; 59(1):1–8.
24. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration time profile and nephrotoxicity. Clin Infect Dis 2009;49(4):507–14.
25. Kalil AC, Murthy MH, Hermsen ED, Neto FK, Sun J, Rupp ME. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med. 2010;38(9):1802-8.69
26. Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 2010; 9(1):9–14.
27. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients:a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66(1):82–98.
28. Star RA. Treatment of acute renal failure. Kidney Int 1998;54(6):1817–31.
29. Hayashi T, Nitta K, Uchida K, et al. Clinical assessment of serum cystatin C as a marker of glomerular filtration rate in patients with various renal diseases. Clinical and Experimental Nephrology 2000;4(2):133-136.
30. Jin L, Shao-jun Y, Wei L, et al. Application in combined measurement of serum levels of cystatin C and urinary microproteins in patients with early renal injury caused by vancomycin. Practical Pharmacy and Clinical Remedies 2012;5:11.
31. Suzuki A, Imanishi Y, Nakano S, et al. Usefulness of serum cystatin C to determine the dose of vancomycin in critically ill patients. J Pharm Pharmacol 2010; 62(7):901-907.
32. Liangos O, Tighiouart H, Perianayagam MC, et al. Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers 2009;14(6):423-31.
33. Ackerman BH, Vannier AM, Eudy EB. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother 1992;36(8):1766–9.
2. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49(3): 325-7.
3 Okamoto G, Sakamoto T, Kimura M, et al . Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients. Clin Biochem 2007;40(7):485-90.
4. Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity. A review. Med Toxicol Adverse Drug Exp 1998;3(5):376–86.
5. Ragab AR, Al-Mazroua MK. Incidence and predisposing factors of vancomycin-induced nephrotoxicity in children. Infect Dis Ther 2013; 2(1): 37–46.
6. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 2012;68(9):1243–55.
7. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52(4):1330–6.
8. Fagon J, Patrick H, Haas DW. Treatment of Gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000;161:753–62.
9. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU- 100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multi-center study. Clin Infect Dis 2001;32(3):402–12.
10. Tanaka A, Aiba T, Otsuka T, et al. Population pharmacokinetic analysis of vancomycin using serum cystatin-C as a market of renal function. Antimicrob Agents Chemother 2010;54(2):778-82.
11. Chung JY, Jin SJ, Yoon JH, Song YG. Serum cystatin C is a major predictive of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations. J Korean Med Sci 2013;28(1):45-54.
12. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med 2010;123(2): 182 e1-7.
13. Khan E, Batuman V, Lertora JJ. Emergence of biomarkers in nephropharmacology. Biomark Med 2010;4(6) 805-14.
14. Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycinassociated nephrotoxicity: a critical appraisal of risk with highdose therapy. Int J Antimicrob Agents 2011;37(2):95–101.
15. Uchida K, Gotoh A. Measurement of cystatin-C and creatinine in urine. Clin Chim Acta 2002; 323(1-2): 121-8.
16. Larsson A, Malm J, Grubb A, Hansson L. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Invest 2004;64(1):25-30.
17. Filler G, Bokenkamp A, Hofmann W, Bricon TL, Martinez-Bru C, Grubb A .Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem 2005;38(1):1-8.
18. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65(4):1416-21.
19. Jin SJ, Bae SC, Kim HW, et al. Evaluation of the effect of initial dose of vancomycin using serum Cystatin C as a marker in elderly patients. Infection and Chemotherapy 2009;41(4):224-9.
20. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV .Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002; 62(1): 237-44.
21. Vaidya VS, Ozer JS, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarkers qualification studies. Nat Biothecnol 2010;28(5):478-85.
22. Zimmermann AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacother 1995;15(1):85–91.
23. Huanga LY, Wanga CY, Jangb TN, Yeh HL. Nephrotoxicity of vancomycin and teicoplanin alone and in combination with an aminoglycoside. Taiwan Pharmaceutical Journal 2007; 59(1):1–8.
24. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration time profile and nephrotoxicity. Clin Infect Dis 2009;49(4):507–14.
25. Kalil AC, Murthy MH, Hermsen ED, Neto FK, Sun J, Rupp ME. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med. 2010;38(9):1802-8.69
26. Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 2010; 9(1):9–14.
27. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients:a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66(1):82–98.
28. Star RA. Treatment of acute renal failure. Kidney Int 1998;54(6):1817–31.
29. Hayashi T, Nitta K, Uchida K, et al. Clinical assessment of serum cystatin C as a marker of glomerular filtration rate in patients with various renal diseases. Clinical and Experimental Nephrology 2000;4(2):133-136.
30. Jin L, Shao-jun Y, Wei L, et al. Application in combined measurement of serum levels of cystatin C and urinary microproteins in patients with early renal injury caused by vancomycin. Practical Pharmacy and Clinical Remedies 2012;5:11.
31. Suzuki A, Imanishi Y, Nakano S, et al. Usefulness of serum cystatin C to determine the dose of vancomycin in critically ill patients. J Pharm Pharmacol 2010; 62(7):901-907.
32. Liangos O, Tighiouart H, Perianayagam MC, et al. Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers 2009;14(6):423-31.
33. Ackerman BH, Vannier AM, Eudy EB. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother 1992;36(8):1766–9.
| Files | ||
| Issue | Vol 7, No 3 (Summer2019) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/jpc.v7i3.2353 | |
| Keywords | ||
| Vancomycin Cystatin C Kidney Injurys KIM-1 | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Elyasi S, Khalili H, Abdollahi A. Comparing Effects of Different Doses of Vancomycin on the Biomarkers of Acute Kidney Injury. J Pharm Care. 2019;7(3):59-66.
